Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty

    loading  Checking for direct PDF access through Ovid



We investigated whether inhibition of oestrogen biosynthesis with the aromatase inhibitor, letrozole, during adolescence improves near-final height in boys with constitutional delay of puberty.

Patients and methods

Seventeen boys with constitutional delay of puberty were randomized to receive testosterone (T) enanthate (1 mg/kg i.m.) every 4 weeks for 6 months in combination with placebo (Pl, n = 8), or the aromatase inhibitor letrozole (Lz, 2·5 mg/day orally) (n = 9), for 12 months. After treatment, patients were followed up until near-final height. Height discrepancy was calculated as near-final height minus mid-parental target height.


The primary end point was the difference in near-final height between the groups treated either with T + Pl or T + Lz. Secondarily, height discrepancy and gain in height standard deviation score (SDS) were analysed in both groups.


Boys treated with T + Lz reached a higher mean near-final height than did boys on T + Pl (175·8 vs. 169·1 cm, respectively, P = 0·04). In T + Lz-treated boys, mean near-final height did not differ from their mid-parental target height (175·8 vs. 177·1 cm, P = 0·38), whereas in T + Pl-treated boys, mean near-final height was lower than mid-parental target height (169·1 vs. 173·9 cm, P = 0·007). T + Lz-treated boys had a greater increment in height SDS over the pretreatment height SDS than T + Pl-treated boys (+1·4 SDS vs.+0·8 SDS, P = 0·03).


Our findings indicate that in adolescent boys an increase in adult height can be attained by use of aromatase inhibitors.

Related Topics

    loading  Loading Related Articles